New chemical strategies for overcoming ATRA resistance in APL cells

Leukemia Research

Volumn 31, Issue 3, 2007, Pages 291-292

  Coradini, Danila ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL PRACTICE; DRUG BINDING; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EDITORIAL; FUSION GENE; HUMAN; HUMAN CELL; LIGAND BINDING; POINT MUTATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECEPTOR AFFINITY;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT MUTATION; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; TRETINOIN;

EID: 33846116718     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.001     Document Type: Editorial

References (12)

1. Melnick A., and Licht J.D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93 (1999) 3167-3215
2. Pandolfi P.P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 10 (2001) 769-775
3. De The H., Lavau C., Marchio A., Chomienne C., Degos L., and Dejean A. The PML-RAR alpha fusion protein mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally alterated RAR. Cell 66 (1991) 675-684
4. Zhu J., Lallemand-Breitenbach V., and de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20 (2001) 7257-7265
5. Soignet S., Fleischauer A., Polyak T., Heller G., and Warrell Jr. R.P. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 40 (1997) S25-S29
6. Liu P., and Han Z.C. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol 78 (2003) 32-39
7. Zhou D.C., Kim S.H., Ding W., Schultz C., Warrell Jr. R.P., and Gallagher R.E. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99 (2002) 1356-1363
8. Meani N., Minardi S., Licciulli S., Gelmetti V., Coco F.L., Nervi C., et al. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene 24 (2005) 3358-3368
9. Chen Z., Guidez F., Rousselot P., Agadir A., Chen S.J., Wang Z.Y., et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 91 (1994) 1178-1182
10. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 19 (2005) 1161-1168
11. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106 (2006) 112-119
12. Komura N., Ikeda Y., Masuda N., Umezawa Y., Ito K., Kizaki M., and Umezawa K. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. Leuk Res 31 (2007) 301-313